Aberdeen Group plc Has $888,000 Position in Iovance Biotherapeutics, Inc. $IOVA

Aberdeen Group plc grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 291.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 516,289 shares of the biotechnology company’s stock after buying an additional 384,489 shares during the quarter. Aberdeen Group plc’s holdings in Iovance Biotherapeutics were worth $888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Accredited Investors Inc. acquired a new position in Iovance Biotherapeutics during the 1st quarter worth about $33,000. WealthTrust Axiom LLC bought a new position in Iovance Biotherapeutics in the 1st quarter worth approximately $33,000. Flputnam Investment Management Co. bought a new position in Iovance Biotherapeutics in the 1st quarter worth approximately $37,000. Gould Asset Management LLC CA acquired a new position in shares of Iovance Biotherapeutics during the first quarter valued at $39,000. Finally, Meeder Advisory Services Inc. acquired a new position in Iovance Biotherapeutics during the 1st quarter valued at about $51,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Down 2.7%

Iovance Biotherapeutics stock opened at $2.18 on Friday. The company has a market capitalization of $788.83 million, a price-to-earnings ratio of -1.77 and a beta of 0.83. The stock’s 50 day moving average is $2.28 and its 200-day moving average is $2.40. Iovance Biotherapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Iovance Biotherapeutics had a negative return on equity of 52.87% and a negative net margin of 161.44%.The business had revenue of $59.95 million for the quarter, compared to the consensus estimate of $67.14 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IOVA shares. Wells Fargo & Company lowered their price target on Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Chardan Capital cut their price objective on Iovance Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. The Goldman Sachs Group cut Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a research note on Tuesday, July 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Iovance Biotherapeutics in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Iovance Biotherapeutics to a “hold” rating in a research report on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.90.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.